elbion AG Increases Series A Financing to EUR35 Million

30-May-2005

elbion AG (elbion) announced that it has increased its Series A Financing from EUR25 million to EUR35 million. Additional investors include Techno Venture Management (TVM), Munich and Boston, Temasek Holdings, Singapore, and Mitsubishi Corporation, Tokyo. They complement lead investors 3i, Burrill & Company and DVC Deutsche Venture Capital as well as co-investors AGF Private Equity, Quintiles PharmaBio Development, BayTech Venture Capital and Marubeni Corporation.

"We are extremely pleased that this financing provides us with adequate resources to swiftly progress our clinical and pre-clinical development programs. With AWD 12-281 and ELB139 already in clinical Phase II we have the potential to generate proof of concept in man in the first half of 2006. Further, ELB353 and ELB526 are drug candidates that are intended to enter the clinic in 2006 as well" said elbion's CEO, Bernd Kastler, and added: "Our top tier financial investor base - together with our strong product portfolio - gives us the chance to evaluate a variety of strategic options in the forthcoming months."

As a result of the transaction, Dr. Christoph Schroeder, Senior Advisor at TVM in Munich, has joined elbion's Supervisory Board.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Total synthesis of a new cancer fighter

Total synthesis of a new cancer fighter

Estetrol proven to have an estrogen antagonistic effect on breast tumour tissue - Pantarhei Bioscience study findings demonstrate the disappearance of breast tumours during treatment with the human fetal estrogen Estetrol

Acacia Pharma initiates Phase IIA study with APD209 in cancer cachexia patients

MorphoSys und Astellas beginnen Antikörperpartnerschaft - Dritte therapeutische Allianz für MorphoSys in Japan

Addex Parkinson's Product Progressing in Early Clinical Trials

ArGEN-X initiates Phase Ib study of ARGX-110 in cancer

Prometic Finalizes Major Technology Licencing Agreement in Tunisia

Doug Berthiaume to Retire as Chairman of the Board of Waters Corporation - Chris O'Connell Elected as New Chairman

Horizon Discovery and Fox Chase Cancer Center announce collaboration to apply rAAV gene targeting in mouse embryonic stem cells and research into EGFR-therapy resistance. - Collaboration will establish a new Center Of Excellence in Mammalian Gene Editing

Hybrigenics receives first patent grant on chemical inhibitors of Ubiquitin-Specific Proteases

Aastrom Biosciences and Zellera AG Announce the Initiation of a Clinical Trial for Bone Grafting in Spain - Aastrom's Proprietary TRCs to be Utilized in Second European Clinical Study to Treat Major Bone Fractures

Movetis Announces Start of a Phase IIa trial for M0002 in Ascites